320407-92-9

Basic information

• Product Name: 4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE
• Synonyms: 4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE;3-Chloro-4-Methoxybenzyl broMide;-2-chloro-1-methoxybenzene
• CAS NO: 320407-92-9
• Molecular Formula: C₈H₈BrClO
• Molecular Weight: 235.51
• Product Categories: pharmacetical
• Mol File: 320407-92-9.mol

Chemical Properties

• Boiling Point: 272.95°C at 760 mmHg
• Flash Point: 118.876°C
• Appearance: /
• Density: 1.521g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE(320407-92-9)
• EPA Substance Registry System: 4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE(320407-92-9)

Safety Data

• Hazardous Substances Data: 320407-92-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE is used as a key intermediate in the production of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE is utilized as a precursor for the synthesis of various agrochemicals, including pesticides and herbicides. Its reactivity and stability contribute to the effectiveness of these products.
Used in Organic Synthesis:
4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE is employed as a versatile building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications.
Safety Precautions:
Due to its toxic nature, 4-BROMOMETHYL-2-CHLORO-1-METHOXYBENZENE should be handled with care to avoid skin, eye, and respiratory irritation. It should be stored in a cool, dry place, away from heat and ignition sources to prevent potential hazards.

InChI:InChI=1/C8H8BrClO/c1-11-8-3-2-6(5-9)4-7(8)10/h2-4H,5H2,1H3

Upstream product

• 14503-45-8 3-chloro-4-methoxybenzyl alcohol 
• 14425-64-0 4-methoxyphenethyl bromide 
• 109418-69-1 C₈H₈ClO⁽¹⁺⁾ 
• 613233-75-3 p-(methylthio)phenethyl bromide 
• 22002-44-4 2-chloro-1-methoxy-4-methylbenzene 
• 4903-09-7 3-chloro-4-methoxy-benzaldehyde 

Downstream Products

• 848044-17-7 tert-butyl 3-chloro-N-(diphenylmethylene)-O-methyl-D-tyrosinate 
• 871708-06-4 6-[(3-chloro-4-methoxyphenyl)methoxy]-1H-indazol-3-amine 

Relevant articles and documents

CHEMICAL COMPOUNDS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar1, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE

The invention relates toa pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the trea

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1-R4 and Ar are as herein defined. Also disclosed in t

METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES

The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for

Indole derivatives as MCP-1 receptor antagonists

A compound of Formula I, wherein: R1 is hydrogen, halo, methyl, ethyl or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, trifluoromethyl, nitro, cyano, trifluoromethoxy, C(O)R7, or S(O)nR7 where n is 0, 1 or 2 and R7 is an alkyl group; R4 is a halo, trifluoromethyl, methylthio, methoxy, trifluoromethoxy or lower alkyl, lower alkenyl or lower alkynyl or COR8 where R8 is lower alkyl; R6 is hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl or COR9 where R9 is lower alkyl; provided that when R1 is hydrogen, halo or methoxy, R2 is hydrogen, halo, methyl, ethyl or methoxy, R5 and R6 are both hydrogen, and one of R3 or R4 is not halo or trifluoromethyl; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonizing an MCP-1 mediated effect in a warm-blooded animal such as a human being.

Total synthesis of cryptophycin 3

The depsipeptide cryptophycin 3 (5) and the cryptophycin analogue 43 were prepared from the corresponding four subunits, The tripeptide analogue 34 was acquired from the starting amino ester 33, which contains fragments D and C. After extension at the car

Imidazopyridinone derivatives and their use as phosphodiesterase inhibitors

A compound (Ia): wherein the variables are defined in the specification, its prodrug or a pharmaceutically acceptable salt thereof useful in the treatment of angina, hypertension etc.

Xanthine phosphodiesterase V inhibitors

A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: For example, a representative comp

Thermodynamic Stabilities of Phenonium Ions Based on Bromide-Transfer Equilibria in the Gas Phase

The thermodynamic stabilities of the phenonium (ethylenebenzenium) ion and ring-substituted derivatives were determined based on the bromide-transfer equilibria in the gas phase. It has been shown that the phenonium ion is 2.4 kcal mol-1 more stable than the t-butyl cation, and that the substituent effect on its stability can be correlated with the Yukawa-Tsuno equation with a ρ value of -12.6 and an r+ of 0.62. An r+ value smaller than unity of the α-cumyl(1-methyl-1-phenylethyl) cation suggested that π-delocalization in the phenonium ion is essentially less effective than through a benzylic π-interaction. On the other hand, the ρ value of -12.6 is distinctly larger than that for the ordinary benzylic carbocation systems, but is comparable to that of the benzenium ion. In addition, it has been found that the r+ value of the phenonium ions in the gas phase is in complete agreement with that for the aryl-assisted process in the acetolysis of 2-arylethyl toluenesulfonates. This suggests that the degree of π-delocalization of the positive charge is the same in the transition state and the intermediate cation. It is concluded that an r+ value of 0.6, which is ranked at a unique position in the continuous spectrum of the resonance demand, is characteristic of the bridged structure of the phenonium ion intermediate and the transition state.